Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)

Abstract

Patients with KRAS wild-type or EGFR mutation-positive NSCLC derived PFS benefits from B+E. However, EGFR IHC, EGFR FISH, and EGFR or KRAS mutation status were not strongly predictive of survival. A larger sample size would be needed to confirm the initial trends observed in this study.

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction

“…1 and 2). AVAPERL [35,36] and ATLAS [37,38] were compared qualitatively with other maintenance trials, but not included in the NMA for efficacy analysis as they did not share a common comparator arm with the other included studies. Characteristics of included studies are provided in Table 1 with details in Appendix Tables A1-2.…”

“…[34] guidelines. a AVAPERL [35,36] and ATLAS [37,38] were not included in the network meta-analysis as there was no common comparator arm with other included maintenance trials.…”

“…Combination maintenance with bevacizumab/pemetrexed in AVAPERL [35,36] and bevacizumab/erlotinib in ATLAS [37,38] versus bevacizumab suggested a trend for OS benefits with significant PFS benefits (Appendix Tables A1-2). Similar to other EGFR TKI maintenance trials, ATLAS [37,38] demonstrated the possibility of substantial OS benefit in the EGFR mutation positive population (OS HR 0.46, 95% CI 0.21-1.02) versus wild-type (OS HR 0.86, 95% CI 0.65-1.15).…”

Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)

“…Previous studies have shown that EGFR‐TKI combined with an antiangiogenic drug (bevacizumab) is effective in the treatment of advanced NSCLC, and can improve patient survival . The clinical study of bevacizumab combined with erlotinib in EGFR‐TKI resistance has also made breakthroughs.…”

“…8 Previous studies have shown that EGFR-TKI combined with an antiangiogenic drug (bevacizumab) is effective in the treatment of advanced NSCLC, and can improve patient survival. [9][10][11][12] The clinical study of bevacizumab combined with erlotinib in EGFR-TKI resistance has also made breakthroughs. In the BELIEF study published at the 2015 European Cancer Congress, patients with advanced nonsquamous NSCLC and EGFR exon 19 deletion or exon 21 (L858R) mutation were enrolled.…”